Search results | cns

Reports

Central Nervous System Partnering Terms and Agreements

The Central Nervous System Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the central nervous system (cns) partnering deals and agreements entered into by the worlds leading healthcare companies.

Insights

UCB Pharma; Combining biology and chemistry to crack the CNS market

UCB Pharma is a global biopharma company developing treatments for diseases of the immune and central nervous system.

Abbott Laboratories focus on CNS and oncology: Pharma partnering activity 2005-2013

Abbott Laboratories announced over 130 pharma partnering / licensing deals since 2005, with over 25 deals in 2012 alone

Lundbeck and Otsuka ink blockbuster CNS deal

In one of the largest partnering deals of the year, Lundbeck and Otsuka have entered into a long-term agreement for the development and commercialization of up to five innovative psychiatric and neuroscience products worldwide

Aspen Pharma: Partnering activity 2009-2014

Aspen Pharma, a global branded and generics pharmaceutical manufacturer, has found a place in the top 50 big pharma companies listed by Current Partnering.

Chugai Pharmaceutical Ltd – Japan’s number one biopharmaceutical company

Chugai Pharmaceutical manufactures, sells, imports and exports pharmaceuticals and has become the leading biopharmaceutical company in Japan.

Regenerative Medicine deal trends article

The field of regenerative medicine is an up and coming new approach of targeting and treating diseases, it involves the repair and restoration of previously damaged tissues or organs in the body. The regenerative medicine market was worth $16bn in 2013 and industry analysts predict that this will leap to over $60bn by 2020. The more »

Nektar Therapeutics – Well respected partner of choice

Nektar Therapeutics is a leading biopharma company developing clinical stage products based upon its advanced polymer conjugate chemistry technology.

Top 50 pharma and biotech companies review – 2009 to 2014

The partnering and M&A  trends and deal analysis of the top 50 pharma and biotech companies reveals a flurry of data that is interesting to observe for efficient deal making.

Bioinformatics: recent life science partnering trend analysis

The bioinformatics partnering deal trend analysis 2009 to 2014 are reviewed in this article.

Genmab: Partnering activity 2009-2014

Genmab, a top big biotech company, headquartered in Denmark is one of the leaders today in the human antibody therapeutics market for cancer treatment.

Events

Sorry, your search returned no results.


Deals

Biogen scoops up CNS programs in $427m acquisition deal

After three years of partnering with Switzerland’s Neurimmune Therapeutics on antibody discovery programs targeting the CNS field, Biogen Idec ($BIIB) has opted to seal their deal with a pact to acquire one of its subsidiaries outright for up to $427.5 million.

To-BBB technologies and Lundbeck join forces on brain delivery of antibodies for CNS diseases

Research collaboration to evaluate delivery of antibodies to the brain for Central Nervous System (CNS) diseases. This research could provide the backbone of new emerging therapies for unserved brain diseases.

PsychoGenics and AstraZeneca enter agreement to identify new treatments for CNS disorders

Teva acquires Auspex for $3.2 billion

Teva and Auspex Pharmaceuticals have entered into a definitive merger agreement

Minerva Neurosciences bags $31 million funding

Minerva Neurosciences will raise approximately $31 million of gross proceeds in a private placement offering to several institutional investors

Alkahest banks $37.5 million in Grifols pact

Grifols will make a major equity investment in Alkahest, and the companies will work together to develop novel plasma-based products for the treatment of cognitive decline in aging

Genzyme and Voyager in $845 million AAV gene therapy pact

Voyager Therapeutics and Genzyme announced a major strategic collaboration to discover, develop and commercialize novel gene therapies for severe CNS disorders

RegenxBio brings in $30 million series C

REGENXBIO announced the completion of a $30 million Series C financing

Otsuka acquires Avanir Pharma for $3.5 billion

Otsuka Pharmaceutical announced an agreement with Avanir Pharmaceuticals, in which Otsuka America, acquires Avanir for USD 3.5 billion in an all-cash tender offer

Impax acquires Tower Holding and its three subsidiaries

Impax Laboratories acquires Tower Holdings for $700 million.